Advertisement

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs

Adam S. Sperling, Michael Burgess, Hasmik Keshishian, Jessica A. Gasser, Shruti Bhatt, Max Jan, Mikołaj Słabicki, Rob S. Sellar, Emma C. Fink, Peter G. Miller, Brian J. Liddicoat, Quinlan L. Sievers, Rohan Sharma, Dylan N. Adams, Elyse A. Olesinski, Mariateresa Fulciniti, Namrata D. Udeshi, Eric Kuhn, Anthony Letai, Nikhil C. Munshi, Steven A. Carr and Benjamin L. Ebert

Article Information

Citation 
vol. 134 no. 2 160-170
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted November 19, 2018
  • Accepted April 26, 2019
  • Published online July 11, 2019.

Article Versions


Contributors 
  • Adam S. Sperling, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Michael Burgess, 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Hasmik Keshishian, 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Jessica A. Gasser, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Shruti Bhatt, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Max Jan, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Mikołaj Słabicki, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 3Broad Institute of MIT and Harvard, Cambridge, MA; 4Division of Translational Oncology, National Center for Tumor Diseases Heidelberg, German Cancer Research Center, Heidelberg, Germany; and
  • Rob S. Sellar, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 3Broad Institute of MIT and Harvard, Cambridge, MA; 5Department of Haematology, UCL Cancer Institute, University College London, London, United Kingdom
  • Emma C. Fink, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Peter G. Miller, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Brian J. Liddicoat, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Quinlan L. Sievers, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Rohan Sharma, 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA;
  • Dylan N. Adams, 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA;
  • Elyse A. Olesinski, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Mariateresa Fulciniti, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Namrata D. Udeshi, 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Eric Kuhn, 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Anthony Letai, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Nikhil C. Munshi, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Steven A. Carr, 3Broad Institute of MIT and Harvard, Cambridge, MA;
  • Benjamin L. Ebert, 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Division of Hematology, Brigham and Women’s Hospital, Boston, MA; 3Broad Institute of MIT and Harvard, Cambridge, MA;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output